#BEGIN_DRUGCARD DB02382

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H14NO9P

# Chemical_IUPAC_Name:
3-carboxy-1-[(2R,3R,4R,5S)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Namn

# HET_ID:
NCN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H14NO9P/c13-8-7(5-20-22(17,18)19)21-10(9(8)14)12-3-1-2-6(4-12)11(15)16/h1-4,7-10,13-14H,5H2,(H2-,15,16,17,18,19)/t7-,8-,9+,10+/m0/s1

# InChI_Key:
InChIKey=JOUIQRNQJGXQDC-AXTSPUMRSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2382

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
335.2039

# Molecular_Weight_Mono:
335.040617563

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1L4F

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.93

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
4.61e+00 g/l

# Primary_Accession_No:
DB02382

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936370

# PubChem_Substance_ID:
46509123

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02312

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@@H]1[C@@H](O)[C@@H](O[C@H]1CO[P@@](O)([O-])=O)[N+]1=CC=CC(=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:05 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L35477

# Drug_Target_1_GenBank_ID_Protein:
535767

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cobT

# Drug_Target_1_Gene_Sequence:
>1101 bp
ATGAGCCGATTATTACGGACGAGACATCTTATGCAGACACTACACGCTTTACTCCGTGAC
ATTCCTGCGCCGGACGCCGAGGCGATGGCGCGTACGCAGCAACATATTGACGGCCTGCTC
AAACCGCCGGGCAGCCTGGGCAGACTGGAAACCTTAGCCGTTCAGCTCGCGGGTATGCCG
GGTCTTAACGGTACGCCGCAGGTAGGTGAAAAGGCGGTGCTGGTGATGTGCGCCGACCAT
GGCGTCTGGGATGAAGGCGTAGCGGTTTCGCCCAAAATCGTGACGGCGATTCAGGCGGCG
AATATGACGCGGGGAACAACCGGCGTATGCGTGCTTGCCGCTCAGGCCGGTGCGAAGGTG
CATGTCATTGATGTCGGTATTGATGCCGAACCTATTCCTGGCGTAGTTAATATGCGCGTC
GCGCGCGGCTGCGGAAATATTGCCGTTGGCCCGGCGATGAGTCGCTTGCAGGCTGAGGCG
CTTTTACTGGAGGTTTCCCGCTGCGCCTGCGACCTGGCGCAACGCGGCGTGACCTTATTT
GGCGTAGGGGAACTGGGAATGGCGAACACTACGCCAGCCGCCGCGATGGTCAGCGTTTTT
ACAGGAAGTGATGCAAAAGAGGTGGTGGGGATTGGCGCGAATCTTCCGCCTTCCCGCATC
GATAATAAAGTGGACGTCGTGCGGCGGGCGATTGCGATTAATCAGCCCAATCCGCGCGAC
GGCATTGATGTGTTGTCGAAGGTGGGTGGTTTTGATCTGGTCGGGATGACCGGCGTGATG
CTTGGCGCGGCAAGGTGTGGCTTACCCGTATTGCTGGATGGCTTTCTTTCCTACTCGGCA
GCGCTGGCGGCCTGTCAGATTGCGCCTGCGGTGAGACCTTATCTGATCCCGTCGCACTTT
TCGGCGGAAAAGGGCGCCCGCATCGCGCTCGCGCATTTGTCTATGGAACCCTATTTGCAT
ATGGCGATGCGGTTAGGTGAAGGAAGCGGCGCGGCGCTGGCGATGCCGATCGTGGAAGCC
GCGTGCGCCATGTTCCACAACATGGGGGAGTTGGCGGCCAGTAATATTGTCCTGCCGGAG
GGGAACGCAAACGCAACATAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
10587435	Cheong CG, Escalante-Semerena JC, Rayment I: The three-dimensional structures of nicotinate mononucleotide:5,6- dimethylbenzimidazole phosphoribosyltransferase (CobT) from Salmonella typhimurium complexed with 5,6-dimethybenzimidazole and its reaction products determined to 1.9 A resolution. Biochemistry. 1999 Dec 7;38(49):16125-35.
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.
7883701	Chen P, Ailion M, Weyand N, Roth J: The end of the cob operon: evidence that the last gene (cobT) catalyzes synthesis of the lower ligand of vitamin B12, dimethylbenzimidazole. J Bacteriol. 1995 Mar;177(6):1461-9.
8501034	Roth JR, Lawrence JG, Rubenfield M, Kieffer-Higgins S, Church GM: Characterization of the cobalamin (vitamin B12) biosynthetic genes of Salmonella typhimurium. J Bacteriol. 1993 Jun;175(11):3303-16.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2264

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
36613

# Drug_Target_1_Name:
Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase

# Drug_Target_1_Number_of_Residues:
356

# Drug_Target_1_PDB_ID:
1L5O

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02277	DBI_PRT

# Drug_Target_1_Protein_Sequence:
>Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase
MQTLHALLRDIPAPDAEAMARAQQHIDGLLKPPGSLGRLETLAVQLAGMPGLNGTPQVGE
KAVLVMCADHGVWDEGVAVSPKIVTAIQAANMTRGTTGVCVLAAQAGAKVHVIDVGIDAE
PIPGVVNMRVARGCGNIAVGPAMSRLQAEALLLEVSRYTCDLAQRGVTLFGVGELGMANT
TPAAAMVSVFTGSDAKEVVGIGANLPPSRIDNKVDVVRRAIAINQPNPRDGIDVLSKVGG
FDLVGMTGVMLGAARCGLPVLLDGFLSYSAALAACQIAPAVRPYLIPSHFSAEKGARIAL
AHLSMEPYLHMAMRLGEGSGAALAMPIVEAACAMFHNMGELAASNIVLPEGNANAT

# Drug_Target_1_Reaction:
beta-nicotinate D-ribonucleotide + 5,6-dimethylbenzimidazole = nicotinate + alpha-ribazole 5'-phosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the synthesis of alpha-ribazole-5'-phosphate from nicotinate mononucleotide (NAMN) and 5,6- dimethylbenzimidazole (DMB)

# Drug_Target_1_SwissProt_ID:
Q05603

# Drug_Target_1_SwissProt_Name:
COBT_SALTY

# Drug_Target_1_Synonyms:
EC 2.4.2.21
N(1)-alpha-phosphoribosyltransferase
NN:DBI PRT

# Drug_Target_1_Theoretical_pI:
6.30

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
BX842577

# Drug_Target_2_GenBank_ID_Protein:
2117242

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
nadC

# Drug_Target_2_Gene_Sequence:
>858 bp
ATGGGGTTATCCGACTGGGAGCTGGCTGCGGCTCGAGCAGCAATCGCGCGTGGGCTCGAC
GAGGACCTCCGGTACGGCCCGGATGTCACCACATTGGCGACGGTGCCTGCCAGTGCGACG
ACCACCGCATCGCTGGTGACCCGGGAGGCCGGTGTGGTTGCCGGATTGGATGTCGCGCTG
CTGACGCTGAACGAAGTCCTGGGCACCAACGGTTATCGGGTGCTCGACCGCGTCGAGGAC
GGCGCCCGGGTGCCGCCGGGAGAGGCACTTATGACGCTGGAAGCCCAAACGCGCGGATTG
TTGACCGCCGAGCGCACCATGTTGAACCTGGTCGGTCACCTGTCGGGAATCGCCACCGCG
ACGGCCGCGTGGGTCGATGCTGTGCGCGGGACCAAAGCGAAAATCCGCGATACCCGTAAG
ACGCTGCCCGGCCTGCGCGCGCTGCAAAAATACGCGGTGCGTACCGGTGGCGGCGTCAAC
CATCGGCTGGGGTTGGGTGATGCCGCGCTAATCAAGGACAACCACGTTGCCGCCGCCGGA
TCCGTGGTAGACGCGCTACGTGCGGTGCGAAATGCTGCACCCGATCTGCCGTGCGAGGTG
GAAGTGGACTCGCTTGAGCAGCTCGATGCCGTGCTGCCGGAAAAACCCGAGCTGATCCTG
CTGGACAATTTTGCGGTGTGGCAGACGCAGACCGCGGTGCAGCGTCGGGACTCGCGCGCG
CCCACCGTCATGCTGGAGTCATCCGGTGGGCTCAGCCTGCAGACGGCGGCGACCTACGCC
GAAACCGGGGTGGACTACCTGGCGGTCGGGGCGCTCACACACTCAGTGCGCGTGCTCGAC
ATCGGCTTGGATATGTAG

# Drug_Target_2_General_Function:
Coenzyme transport and metabolism

# Drug_Target_2_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.
9862811	Sharma V, Grubmeyer C, Sacchettini JC: Crystal structure of quinolinic acid phosphoribosyltransferase from Mmycobacterium tuberculosis: a potential TB drug target. Structure. 1998 Dec 15;6(12):1587-99.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2442

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
29951

# Drug_Target_2_Name:
Nicotinate-nucleotide pyrophosphorylase [carboxylating]

# Drug_Target_2_Number_of_Residues:
285

# Drug_Target_2_PDB_ID:
1QPR

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01729	QRPTase_C
PF02749	QRPTase_N

# Drug_Target_2_Protein_Sequence:
>Nicotinate-nucleotide pyrophosphorylase [carboxylating]
MGLSDWELAAARAAIARGLDEDLRYGPDVTTLATVPASATTTASLVTREAGVVAGLDVAL
LTLNEVLGTNGYRVLDRVEDGARVPPGEALMTLEAQTRGLLTAERTMLNLVGHLSGIATA
TAAWVDAVRGTKAKIRDTRKTLPGLRALQKYAVRTGGGVNHRLGLGDAALIKDNHVAAAG
SVVDALRAVRNAAPDLPCEVEVDSLEQLDAVLPEKPELILLDNFAVWQTQTAVQRRDSRA
PTVMLESSGGLSLQTAATYAETGVDYLAVGALTHSVRVLDIGLDM

# Drug_Target_2_Reaction:
nicotinate D-ribonucleotide + diphosphate + CO2 = pyridine-2,3-dicarboxylate + 5-phospho-alpha-D-ribose 1-diphosphate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Nicotinate D-ribonucleotide + diphosphate + CO(2) = pyridine-2,3-dicarboxylate + 5-phospho-alpha-D-ribose 1- diphosphate

# Drug_Target_2_SwissProt_ID:
O06594

# Drug_Target_2_SwissProt_Name:
NADC_MYCTU

# Drug_Target_2_Synonyms:
EC 2.4.2.19
QAPRTase
Quinolinate phosphoribosyltransferase [decarboxylating]

# Drug_Target_2_Theoretical_pI:
4.88

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB02382
